SEC Form 4 · accession 0001209191-17-053024
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yamo Deniz
Officer — Chief Medical Officer
Period of report
Aug 28, 2017
Accepted (ET)
Sep 15, 2017 · 5:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 31, 2017 | P | 1,375 | $25.40 | A | 5,000 | D | |
| Common Stock | Sep 1, 2017 | P | 1,000 | $24.55 | A | 6,000 | D | |
| Common Stock | Sep 1, 2017 | P | 2,000 | $23.95 | A | 8,000 | D | |
| Common Stock | Sep 5, 2017 | P | 1,000 | $24.20 | A | 9,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Call Option (right to buy) | $30.00 | Aug 28, 2017 | P | 20 | A | Aug 28, 2017 | Oct 20, 2017 | Common Stock | 2,000 | 20 | D |
| Call Option (right to buy) | $22.50 | Sep 5, 2017 | P | 10 | A | Sep 5, 2017 | Nov 17, 2017 | Common Stock | 1,000 | 10 | D |